Preliminary findings from a phase I clinical trial indicate that enfortumab vedotin, an investigational antibody–drug conjugate targeting nectin-4, shows considerable efficacy in metastatic urothelial carcinoma. Robust responses were seen even among patients with disease progression on platinum chemotherapy and/or immune checkpoint blockade.
http://ift.tt/2w1YSBm
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου